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Abstract
Background: While type 2 diabetes mellitus (DM) is a common condition of midlife women, few studies have
examined its influence on the symptom features of menopause. To explore this relationship, we conducted a
study of symptom patterns of diabetic patients using a random sample of female veterans receiving care in the
Veterans Affairs Healthcare system.
Methods: A cross-sectional comparison was conducted with three groups of postmenopausal respondents (ages
45–60 years) to a mailed national survey who also consented to clinical data access: no diabetes (n = 90),
diabetes with better glucose control (hemoglobin A1c [HbA1c] £ 7%, n= 135) and diabetes with worse glucose
control (HbA1c> 7%, n= 102).
Results: Respondents, on average, were obese (body mass index: 33.9 – 0.4 kg/m2), 11.30– 0.2 years post-
menopause, with more than one chronic illness. Despite higher body mass index and increased comorbidities in
women with diabetes compared with nondiabetic women, measures of mental health (anxiety, depressed mood,
stress) were similar across groups. The pattern of menopause symptoms did not differ by group. Muscle aches/
joint pain was the most prevalent symptom (78.6%), followed by vasomotor symptoms (74.4%). Respondents
with elevated HbA1c demonstrated higher total menopausal symptom severity scores (DM-HbA1c> 7:
15.4– 0.8 vs. DM-HbA1c£ 7%: 12.2– 0.8 vs. No diabetes: 12.3– 0.8; p= 0.006) than the other two groups.
Conclusions: In postmenopausal female veterans with diabetes, glucose control is associated with the severity
of those symptoms commonly attributed to menopause. Joint pain is an important part of the postmenopausal
symptom complex in this population.
Introduction
L ittle is known about menopausal symptom patterns inwomen with type 2 diabetes, an increasingly common
chronic health condition during middle age.1 Prior studies
suggest that chronic disease can adversely affect the post-
menopausal experience.2–5 In the case of diabetes, many
symptoms overlap with those marking the end of reproduc-
tive life. For example, vaginal irritation,6 urinary inconti-
nence,7 and disturbed sleep8 are common features of both
diabetes and the menopausal transition.9 Moreover, the
compromised glycemic control of diabetes has been impli-
cated as a mediator of hot flash severity,10 one of the most
troubling postmenopausal complaints.
Despite this prior work, the interaction between diabetes
and menopause has not been evaluated in a United States
(U.S.) population, where diabetes rates are pronounced. One
investigation in Mexico of menopausal symptoms docu-
mented higher rates of depressed mood in diabetic women
compared with controls, although levels of anxiety and sleep
disturbances were similar.11 A second study from Mexico
found no difference in vasomotor symptoms between healthy
and diabetic subjects,12 but neither study carried out a com-
prehensive symptom assessment or examined the influence of
glucose control. Among postmenopausal Ecuadorian women
with and without metabolic syndrome, affected participants
demonstrated higher physical and psychological symptom
scores but similar sexual and vasomotor symptom scores
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compared with healthy controls.13 However, only a small
proportion of those with metabolic syndrome (16%) dem-
onstrated hyperglycemia, making it difficult to determine the
relationship between elevated glucose and these symptoms.
Finally, in Korea, Lee and colleagues14 reported a higher
prevalence of somatic menopausal symptoms (hot flashes,
sleep disturbances, muscle and joint aches) in those post-
menopausal subjects with the metabolic syndrome compared
with the unaffected controls, but glucose control was not
examined as a factor. The purpose of this study was to de-
scribe the postmenopausal symptom experience in U.S. wo-
men with type 2 diabetes and to examine the association
between glucose control and symptom severity.
Materials and Methods
Design and sample
Taking advantage of the well-characterized medical record
system used by the Veterans Health Administration (VHA),
we conducted a cross-sectional retrospective study of a ran-
dom sample of female veterans receiving healthcare services
from the VHA. The study employed a mailed, self-adminis-
tered survey and, with consent, the extraction of electronic
record data relevant to the study.
After approval by the Institutional Review Boards at the
Ann Arbor Veterans Affairs Medical Center and the Uni-
versity of Michigan, Ann Arbor, potential participants, ages
45–60 years, who had received care in the last 2 years were
identified from a review of national VHA data sources (labo-
ratory, pharmaceutical, service utilization). Women were
classified as having diabetes if they had two or more outpatient
visits with a diabetes-related diagnosis code per year in the past
24 months or at least one inpatient hospitalization with a di-
abetes-related diagnosis code and at least two documented
hemoglobin A1c (HbA1c) values in the past 12 months.
Women with diabetes were characterized using their most
recent HbA1c value as a measure of glucose control. Optimal or
‘‘better’’ glucose control was defined as HbA1c£7% and sub-
optimal or ‘‘worse’’ glucose control was defined as HbA1c>
7%.15–16Although theAmericanDiabetesAssociation15 and the
Veterans Affairs/Department of Defense Diabetes Mellitus
Clinical PracticeGuideline16 recommend individualizedHbA1c
targets, based on patient characteristics (e.g., life expectancy,
disease severity, patient preferences), because the study popu-
lationwas fairly young and expected to be relatively healthy, for
research purposes, we set the cut-off value for HbA1c at 7%.
Additional selection criteria included the following: no
current or past 2 years history of substance abuse, no current or
past history of severe psychiatric illness, renal failure, or gy-
necological cancer; and no current or past 6 months use of
hormone products, corticosteroid or anabolic steroids, anti-
psychotic medications, or more than two classes of psychoac-
tive medications on a daily basis. Postmenopause was defined
as amenorrhea for> 12months or hysterectomywith orwithout
ovariectomy and currently not taking hormones. Reproductive
status was determined by self-report on the study survey
(havingmenstrual cycles or amenorrhea for at least 12months).
If participants reported amenorrhea, theywere asked to specify
the cause: natural menopause, hysterectomy (only the uterus),
hysterectomy with removal of the ovaries, other causes.
A stratified, random sample of 900 women meeting the
above criteria (300 without diabetes, 300 with diabetes and
optimal or better glucose control, and 300 with diabetes and
suboptimal or worse glucose control) was selected for the
mailed survey. Based on a sample size calculation for 80%
power and an alpha significance level of 0.05, 100 subjects
were needed per study group. The estimated recruitment pool
was multiplied by three to accommodate the anticipated re-
sponse rate and the loss of participants expected to fail the
survey’s menopause criteria. Potential participants were
mailed an invitation to participate, including a cover letter
with an informational brochure, the survey, two copies of the
consent form, a stamped return envelope, and a token of
appreciation ($10 gift card). The consent form requested
permission to examine participant’s health record data for
two years prior to the study and one year after completing the
survey to extract clinical information, such as HbA1c. A
reminder letter was sent 2 weeks after the first mailing, fol-
lowed by a second survey and consent form 2 weeks later.
Survey data collection closed 4 weeks after the third mailing.
Measures
The survey collected information about menopause status,
the postmenopausal symptom experience, health status, co-
morbid conditions, diabetes symptoms and self-management
behaviors, sociodemographic characteristics, height and weight
to calculate body mass index (BMI), and current medication
use. Depressive symptoms, anxiety, and perceived stress were
also assessed. Glycemic control was measured by serum
HbA1c and used to differentiate the groups with diabetes.
Menopause symptom prevalence and severity were mea-
sured with the Menopausal Symptom List (MSL).17 Partici-
pants indicated the prevalence and severity of 12 symptoms
in the past month. Symptom severity was rated on a four-
point scale from 0 (none) to 3 (severe). Individual symptom
severity scores were summed to calculate the total MSL se-
verity score (range 0–36).
Respondents prospectively recorded the frequency and se-
verity (mild, moderate, severe) of hot flashes and night sweats
for two consecutive days. A hot flash score was calculated
using the formula: [number of mild hot flashes]+ [2· number
of moderate hot flashes]+ [3· number of severe hot flashes],
and a mean value for the two days determined. A zero score
was recorded for respondents who indicated no symptoms
during the two-day period. Perceived health status was as-
sessed using the 12-item Short Form Health Survey.18 De-
pressive symptoms were measured using the short form of the
Center for Epidemiologic Studies Depression Scale-10,19
perceived anxiety was measured by the Generalized Anxiety
Disorder scale,20 and the Perceived Stress Scale-10 measured
the respondent’s appraisal of life stressors.21
Statistical analysis
Analyses were performed using STATA version 10.0
(Stata Corporation, College Station, TX). Descriptive statis-
tics were used to characterize the sample and study groups.
Skewed physiologic variables were log-transformed to en-
sure normality. Group differences in categorical variables
were compared using chi-squared tests; group differences in
continuous variables were compared by t-tests and analysis of
variance with post-hoc Bonferroni correction. Associations
between glucose control status and menopause symptom
severity, controlling for known theoretical and empirical
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covariates including BMI, ethnicity, smoking, age of meno-
pause, and type of menopause (natural, induced) were exam-
ined using multivariable regression methods. As longitudinal
studies demonstrate that women with a history of mood dis-
order report increased psychological symptoms during the
menopausal transition,22–23 the respondent’s self-report of a
mental health diagnosis (depression, anxiety, posttraumatic
stress disorder [PTSD]) was used in the regression analyses to
control for the influence of having a diagnosed mood distur-
bance (altered mood status). Because the number of years
postmenopause and age of menopause are inverse parame-
ters, only age of menopause was included in the regression
analyses. Ethnicity was examined as a four-level categorical
and a dichotomous variable (white/non-white) in analyses for
group differences and to assess associations with the depen-
dent variable. A two-tailed p value of < 0.05 was regarded as
statistically significant. As the amount of missing data in the
major variables was £ 6%, listwise deletion was used in all
analyses.
Results
A total of 537 surveys were returned (59.6%); most re-
spondents (n = 506; 94%) consented to clinical data access.
Upon review of the survey and extracted data, 210 cases were
excluded: 112 women were still menstruating and another 98
reported the use of exclusionary medications (e.g., hormone
therapy) or clinical conditions (e.g., cancer), or submitted
incomplete surveys. The final sample of 327 subjects in-
cluded: 90 without diabetes, 135 with diabetes and optimal
HbA1c values, and 102 with elevated HbA1c values.
Participant characteristics
Participants were on average 55 years of age, obese, and
11.3 years postmenopause. The majority of participants were
white (58%), with a range of other ethnic/minority groups
represented. Most participants did not smoke (n = 282; 86%).
More than half of the women (n = 178; 56%) were working
full or part-time; most (n = 183; 59%) household income
levels were below the U.S. median.24
Table 1 presents the characteristics of the study groups.
Women without diabetes were younger, of lower BMI, had
fewer self-reported comorbid conditions, and better physical
health. Race/ethnicity did not differ across groups whether
assessed using four categories (white, black, Hispanic, other)
or as white/non-white. Mental health scores and levels of
anxiety, perceived stress, and depressive symptoms were
similar across the study groups.
Menopause characteristics
Among women with natural cessation of menses, the av-
erage age of menopause was 49.2 years, which did not differ
by diabetes status. More than half of the respondents (55.1%;
n = 179) reported an induced menopause for surgical or other
reasons (trauma, drug exposure) at an early age (mean 39.1
years). Hysterectomy features were similar across all three
groups (Table 2).
Menopausal symptom prevalence
For the full sample, muscle and joint aches, hot flashes, and
trouble sleeping were the most prevalent symptoms which
did not differ by study group (Table 3). Headaches and
anxiety were more prevalent in those with elevated HbA1c
values.
Menopausal symptom severity
Symptom severity scores were highest for muscle and joint
aches followed by hot flashes, and trouble sleeping; head-
aches received the lowest severity scores (Table 4). Women
with worse glucose control demonstrated more severe anxi-
ety and sleep disturbances than those with better glucose
control, more severe mood swings than women without di-
abetes, and more intense headaches compared with both
groups. Total MSL severity scores were higher in diabetic
women with worse glucose control compared with the other
two groups (Table 4).
Factors associated with menopausal symptom severity
In the full sample, cigarette smoking and a diagnosis of
altered mood were positively associated with menopause
symptom severity after controlling for diabetes status and
sociodemographic, clinical, and menopause characteristics
(Table 5). Among women with diabetes, worse glucose
control (b = 0.15; p= 0.03), smoking, and a diagnosis of al-
tered mood demonstrated a positive association with per-
ceived menopause symptom severity after adjustment for
other covariates.
Discussion
Little is known about menopausal symptom patterns in
women with type 2 diabetes, which is increasingly prevalent1
and has many symptoms that may overlap with those marking
the end of reproductive life.6–8 This study describes the
menopause history and symptom experience of women with
and without type 2 diabetes receiving care in the VHA sys-
tem. Our results suggest that despite higher BMI and in-
creased disease-related comorbidities, women with diabetes
experienced natural and induced menopause at the same age
and reported similar postmenopausal symptoms as their
nondiabetic peers. Muscle and joint aches, hot flashes, and
trouble sleeping were the most common postmenopausal
complaints, consistent with results from cohort studies of
healthy and ethnically diverse women.25–30
The rate of surgical menopause in our sample (approxi-
mately 50%) was higher than estimates reported (between
33% and 45%) for the general population31–32 and could be
related to the presence of risk factors such as low socioeco-
nomic status and minority ethnicity.33–34 Our findings are
congruent with a study of hysterectomy prevalence in female
veterans,35 which documented that rates varied by age, in-
creasing from 12% in 18–39 year olds to 35% among 40–49
year olds and 57% in women aged 50 years or older.35 Pre-
dictors included older age, multiparity, marital status, health
conditions, and PTSD. Coupled with our findings, these data
suggest that veterans using VHA services may have increased
hysterectomy prevalence compared with the general popu-
lation and further investigations are warranted.
The mean age of menopause was 39 years among women
with induced menopause and 49 years in those with natural
menopause, which is earlier than the mean age of 51 years
among North American women.9 Respondent characteristics
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such as chronic illness,36 obesity,37 and African American
and Hispanic ethnicity38 have been associated with early
menopause and may have contributed to this finding.
Symptom prevalence rates in our sample were higher than
rates documented in cohort studies of healthy women. Ap-
proximately 69% of our respondents had trouble sleeping,
compared with rates ranging from 43% to 50% in other post-
menopausal cohorts.25–26,30 Muscle and joint aches, hot fla-
shes, and sad moodwere reported at rates up to 79%, 75%, and
61% in this study compared with rates of 55%, 49%, and 22%,
Table 2. Type of Menopause by Study Group
Entire
sample
Women without
diabetes
Women with
diabetes HbA1c £ 7%
Women with
diabetes HbA1c > 7%
(n = 325) (n= 90) (n = 133) (n = 102) pa
Type of menopause 0.75
Natural 146 (44.9) 43 (47.8) 60 (45.1) 43 (42.2)
Inducedb 179 (55.1) 47 (52.2) 73 (54.9) 59 (57.8)
Surgical causes 0.09
Hysterectomy with ovariectomy 89 (51.7) 25 (54.3) 41 (59.4) 23 (40.4)
Hysterectomy 83 (48.3) 21 (45.7) 28 (40.6) 34 (59.6)
Values are n (%).
aChi-squared with Fisher’s exact test.
bIncludes surgical procedures (hysterectomy with ovariectomy, hysterectomy; n= 172, 52.9%) and other causes (trauma, clinical
conditions, medications; n = 7, 2.2%).
Table 1. Clinical and Demographic Characteristics by Study Groups
Women without
diabetes
Women with
diabetes (HbA1c £ 7%)
Women with
diabetes (HbA1c > 7%)
(n = 90) (n= 135) (n= 102) p
Age in years 53.6 – 0.5a 55.5– 0.4 55.5– 0.5 0.003
Age of menopause 44.8 – 0.8 43.9– 0.7 42.5– 0.9 0.13
Years postmenopause 8.9 – 0.8b 11.6– 0.8 13.0– 0.9 0.007
BMI (kg/m2)c 30.8 – 0.6d 34.8– 0.6 35.9– 0.7 < 0.001
Ethnicity 0.47
White 57 (65) 80 (60.2) 50 (50)
Black 24 (27) 36 (27) 32 (32)
Hispanic 4 (5) 9 (6.8) 9 (9)
Othere 3 (3) 8 (6) 9 (9)
Medical conditions 2.8 – 0.2d 5.3 – 0.2 5.5 – 0.3 < 0.001
Altered mood diagnosis 22 (25%) 48 (36%) 36 (37%) 0.14
Neuropathy diagnosisf 11 (12%) 34 (26%) 38 (39%) < 0.001
Tobacco usef 15 (17) 11 (8) 19 (19) 0.04
HbA1c (%)
c,g 6.4 – 0.05 8.9 – 0.2 < 0.001
Age of diabetes diagnosisg 49.8– 0.5 45.4– 0.8 < 0.001
Diabetes duration in yearsg 5.7 – 0.5 10.1– 0.7 < 0.001
Perceived Stress Scale–10 score 14.8 – 0.8 14.6– 0.7 16.4– 0.8 0.21
Generalized anxiety disorder–7 score 5.2 – 0.6 5.0 – 0.5 5.4 – 0.5 0.86
CESD–10 score 9.0 – 0.7 9.5 – 0.6 10.8– 0.7 0.14
Physical health score 43.3 – 1.3h 38.6– 1.1 39.1– 1.2 0.012
Mental health score 43.8 – 1.2 44.9– 1.0 41.7– 1.2 0.12
SSRI, SNRI or gabapentin usef 18 (20%) 43 (32%) 33 (32%) 0.04
Values are mean – standard error of the mean (SEM) or n (%).
aANOVA with post hoc Bonferroni: p = 0.005 vs. women with better glucose control (HbA1c £ 7%); p = 0.012 vs. women with worse
glucose control (HbA1c > 7%).
bANOVA with post hoc Bonferroni: p = 0.005 vs. women with worse glucose control (HbA1c> 7%).
cNormality ensured by logarithmic transformation.
dANOVA with post hoc Bonferroni: p < 0.001 vs. women with better glucose control (HbA1c £ 7%); p< 0.001 vs. women with worse
glucose control (HbA1c > 7%).
eOther: Native American Indian (n= 4); Asian (n = 2); Hawaiian Pacific Islander (n = 1); multiracial women (n = 14, 10 of whom identified
as Native American Indian).
fChi-squared with Fisher exact test.
gt-Test.
hANOVA with post hoc Bonferroni: p = 0.014 vs. women with better glucose control (HbA1c £ 7%); p= 0.06 vs. women with worse
glucose control (HbA1c > 7%).
ANOVA, analysis of variance; BMI, body mass index; CESD-10, Center for Epidemiologic Studies Short Depression Scale; HbA1c,
hemoglobin A1c; SNRI, selective norepinephrine receptor inhibitor; SSRI, selective serotonin receptor inhibitor.
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respectively, in the postmenopausal subsample of the multi-
ethnic Study of Women Across the Nation (SWAN).22,26,38
This high level of symptom reporting may be related to
characteristics of the sample. As a group, the respondents
were obese, with a third reporting a diagnosis of altered
mood. Collectively, these clinical factors, along with the high
rates of hysterectomy, have been linked to higher rates of
vasomotor, sleep, somatic, genitourinary, and mood symp-
toms in the postmenopause.23,26,39–42,45 Increased symptom
reporting has also been associated with African American
and Hispanic ethnicity,26,39,43–44 groups well represented in
this sample. Traumatic life events are another correlate of
menopause symptoms,46 and although not assessed in this
investigation, female veterans are often considered a trauma-
exposed group47 and potentially vulnerable to a magnified
symptom response. Lastly, other studies48–49 have docu-
mented that veterans report more symptoms compared with
the general population, with increased symptom rates ob-
served in females compared with males.49
These symptom prevalence rates are consistent with rates
observed in the few postmenopausal studies of women with
chronic illness. Two-thirds of the participants had diabetes as
part of a set of five chronic health conditions; the nondiabetic
women reported two to three comorbid conditions. In addition
to diabetes, the most prevalent comorbidities were hyperten-
sion (n= 234; 73%), hyperlipidemia (n= 208; 65%), and os-
teoarthritis (n= 155; 48%). Among post-polio survivors,
Kalpakjian et al.5 demonstrated postmenopausal symptom
prevalence rates in the 80% range for vasomotor, sleep, mood,
sexual, and cognitive symptoms. In HIV-infected women,2
Table 3. Menopause Symptom Prevalence by Study Groups
Entire
sample
Women without
diabetes
Women with
diabetes (HbA1c £ 7%)
Women with
diabetes (HbA1c > 7%)
(n= 313) (n = 87) (n= 129) (n= 97) p
Muscle/joint aches 245 (78.6) 68 (78.2) 100 (77.5) 77 (80.2) 0.91
Hot flashes 233 (74.4) 66 (75.9) 90 (70.0) 77 (79.4) 0.25
Trouble sleeping 214 (68.6) 60 (69.0) 81 (62.3) 73 (76.0) 0.11
Memory 203 (65.0) 57 (65.5) 76 (58.9) 70 (72.9) 0.10
Irritable 199 (64.2) 55 (63.2) 79 (61.7) 65 (68.4) 0.56
Sad or blue 191 (61.2) 50 (57.5) 78 (60.5) 63 (65.7) 0.52
Decreased libido 178 (58.4) 52 (60.5) 66 (52.0) 60 (65.2) 0.13
Leaking urine 179 (57.2) 45 (51.7) 71 (55.0) 63 (65.0) 0.16
Mood swings 169 (54.2) 44 (50.6) 66 (51.2) 59 (61.2) 0.23
Anxiety 165 (52.9) 48 (55.2) 58 (45.0) 59 (61.5) 0.05
Headaches 147 (47.0) 37 (42.5) 52 (40.3) 58 (59.8) 0.01
Vaginal dryness 141 (45.2) 42 (48.3) 52 (40.3) 47 (50.0) 0.35
Values are n (%).
Chi-squared with Fisher exact test.
Table 4. Menopause Symptom Severity by Study Group
Women without
diabetes
Women with
diabetes (HbA1c £ 7%)
Women with
diabetes (HbA1c > 7%)
(n = 87) (n= 129) (n = 97) p
Muscle/joint aches 1.6 – 0.1 1.7 – 0.07 1.7 – 0.07 0.65
Hot flashes 1.3 – 0.1 1.2 – 0.07 1.4 – 0.07 0.34
Trouble sleeping 1.4 – 0.1 1.3 – 0.08 1.7 – 0.08a 0.05
Decreased libido 1.2 – 0.1 1.2 – 0.09 1.5 – 0.09 0.14
Irritable 1.0 – 0.1 1.0 – 0.07 1.2 – 0.07 0.29
Memory 0.9 – 0.09 0.9 – 0.06 1.1 – 0.06 0.31
Leaking urine 0.9 – 0.1 0.9 – 0.07 1.1 – 0.07 0.15
Sad or blue 0.9 – 0.1 1.0 – 0.07 1.2 – 0.07 0.11
Mood swings 0.8 – 0.1 0.9 – 0.07 1.1 – 0.07b 0.03
Anxiety 0.8 – 0.09 0.7 – 0.07 1.1 – 0.07c 0.03
Vaginal dryness 0.9 – 0.1 0.7 – 0.06 0.9 – 0.06 0.29
Headaches 0.7 – 0.1 0.7 – 0.07 1.0 – 0.07d,e 0.009
Total MSL score 12.3 – 0.8 12.2 – 0.8 15.4 – 0.8b,f 0.006
Hot flash score 10.5 – 1.4 9.6 – 0.9 9.5 – 0.9 0.85
Values are mean – SEM; data were analyzed using ANOVA with post hoc Bonferroni.
ap= 0.05 vs. women with better glucose control (HbA1c £ 7%).
bp= 0.03 vs. women without diabetes.
cp= 0.04 vs. women with better glucose control (HbA1c £ 7%).
dp= 0.016 vs. women with better glucose control (HbA1c £ 7%).
ep= 0.04 vs. women without diabetes.
fp = 0.009 vs. women with better glucose control (HbA1c£ 7%).
MSL, Menopause Symptom List.
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high rates (> 70%) of psychological and genitourinary symp-
toms were noted, while elevated rates (> 80%) of decreased
libido, muscle and joint stiffness, and cognitive symptoms
were described in postmenopausal women with the metabolic
syndrome.50 These data suggest that comorbid, chronic con-
ditions may be an important contributor to increased symptom
reporting with menopause.
We also report for the first time that glucose control was a
key correlate of menopause symptom severity in women with
diabetes, independent of the well-described influence of
obesity and ethnicity.Womenwith worse glucose control had
higher symptom severity scores than their peers with better
control who were of similar body size, years post menopause,
and psychological status. Moreover, menopause symptom
severity scores were similar between diabetic women with
optimal glucose control and the nondiabetic cohort, despite
differences in BMI and disease-related comorbidities. These
data suggest that interventions targeting glucose control
may improve the postmenopausal symptom experience for
women with diabetes.
The increased severity of anxiety and mood symptoms
among diabetic women with worse glucose control is not
surprising. Depressed mood occurs in 25%–45% of adults
with diabetes,51–52 and up to 40% of diabetic patients expe-
rience anxiety,53 with women more affected than men.52–53
Both conditions (anxiety, depression) have been associated
with poor glycemic control.52,54–56 While the association of
these symptoms with diabetes is well documented, few
studies have specifically examined them in diabetic midlife
women, much less in the context of the postmenopause.57
With only cross-sectional data, it is difficult to determine if
the greater severity of psychological symptoms observed
here is related to menopause, diabetes, or an interaction be-
tween both conditions.
Symptoms of diabetes and depression can be inter-
connected and difficult to disentangle, which may be espe-
cially true in the context of the postmenopause. For example,
somatic symptoms such as fatigue, cognitive complaints of
impaired concentration and psychological concerns of emo-
tional lability are symptoms associated with all three condi-
tions. Evidence from meta-analyses is conflicting, showing
that depression increases diabetes risk and worsens glucose
control,58 and likewise diabetes increases risk for depres-
sion.59 In another meta-analysis, a differential impact of these
conditions was observed: depressed mood imposed a 60%
increased risk for type 2 diabetes, while diabetes incurred a
15% rise in depression risk.60 Future longitudinal studies that
characterize women using the stages of reproductive aging61
would help clarify these relationships.
Vasomotor symptoms were similar across the study groups
and corroborate some,12,13 but not all,14 findings from inter-
national studies in women with diabetes or the metabolic
syndrome. Although a hypothetical link has been pro-
posed,10,62 there is little data describing the relationship be-
tween vasomotor symptoms with glucose and insulin
parameters even in healthy cohorts. One investigation of
nondiabetic Swedish women showed no relationship between
vasomotor symptoms and glucose values,63 while a longitu-
dinal study of multi-ethnic U.S. women demonstrated that hot
flashes were associated with insulin resistance.62 Given the
emerging evidence that vasomotor symptoms may be a sur-
rogate marker for cardiovascular disease risk,64 more studies
are needed.
With the known influence of the selective serotonin and
norepinephrine receptor inhibitors and gabapentin on the
relief of vasomotor symptoms,65–67 it is possible that the
higher use rates of these medications in women with diabetes
(Table 1) may have masked potentially higher rates of
Table 5. Multivariate Analysis: Menopause Symptom Severity Score
Variable
Unstandardized
beta (95% CI)
Standardized
beta p R2
Model 1, all women < 0.001 0.15
Diabetes HbA1c > 7% 2.10 ( - 0.34–4.55) 0.12 0.09
Diabetes HbA1c £ 7% - 0.45 ( - 2.63–1.74) - 0.028 0.68
Altered mood disorder 4.53 (2.51–6.50) 0.27 < 0.001
Tobacco use 3.61 (0.96–6.21) 0.16 0.008
Age of menopause - 0.13 ( - 0.28–0.024) - 0.13 0.08
Ethnicity, Black 0.41 ( - 1.70–2.51) 0.02 0.64
Ethnicity, Hispanic 1.60 ( - 1.74–4.93) 0.06 0.35
Ethnicity, othera 3.13 ( - 0.33–6.60) 0.10 0.08
BMIb 1.27 ( - 3.34–5.80) 0.03 0.61
Type of menopause (natural, induced) 0.09 ( - 2.21–2.40) 0.005 0.94
Model 2, women with diabetes < 0.001 0.14
Diabetes HbA1c > 7% 2.43 (0.21–4.66) 0.15 0.03
Altered mood disorder 4.11 (1.82–6.40) 0.25 < 0.001
Tobacco use 4.30 (1.05–7.53) 0.18 0.01
Age of menopause - 0.11 ( - 0.30–0.061) - 0.11 0.19
Ethnicity, Black 0.64 ( - 1.93–3.21) 0.04 0.63
Ethnicity, Hispanic 1.71 ( - 2.14–5.60) 0.06 0.38
Ethnicity, othera 2.94 ( - 0.99–6.90) 0.10 0.14
BMIb 1.74 ( - 3.80–7.29) 0.04 0.53
Type of menopause (natural, induced) 0.35 ( - 2.42–3.13) 0.02 0.80
aOther: Native American Indian (n= 4); Asian (n = 2); Hawaiian Pacific Islander (n = 1); multiracial women (n = 14, 10 of whom identified
as Native American Indian).
bBMI: log transformed to ensure normality.
POSTMENOPAUSAL SYMPTOMS, FEMALE VETERANS, DIABETES 501
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
vasomotor symptoms in these women. Further, the women
with diabetes had higher rates of neuropathy that may have
diminished peripheral sensitivity. Future studies in diabetic
women using skin conductance devices to measure vaso-
motor events paired with glucose monitoring would more
accurately characterize these symptoms.
Muscle and joint aches were reported with the greatest
prevalence and severity by the entire sample. Musculoske-
letal complaints are common and emerge differentially
across the menopause transition, reported by 20%–80% of
women.25,30,68–69,71 An accumulating body of evidence from
cross-sectional and longitudinal studies has demonstrated a
relationship between menopause and the complaints of joint
pain/stiffness, independent of aging 30,68,71 and obesity.30,68–69
Retrospective surveys in women with pain complaints also
indicate migraine headache and back pain improved or dis-
appeared in menopause, while osteoarticular pain and tension
headache presented or worsened.72–73
Female gender has also been repeatedly associated with an
increased risk for osteoarthritis, especially around the age
of 50.70,74,77,84 In the Framingham cohort, the prevalence of
symptomatic degenerative changes of the knee and hand
were more prevalent in women than men.75–76 Further,
greater physical function limitations were observed in post-
menopausal women compared with premenopausal SWAN
participants independent of aging, BMI and depressive
symptoms.78 Moreover, hormone therapy trials demonstrate
evidence that exogenous estrogen improves muscle and joint
symptoms. In the Women’s Health Initiative (WHI), treat-
ment with estrogen plus progestin reduced joint pain and
stiffness and prevented the onset of musculoskeletal com-
plaints in participants who were asymptomatic at baseline.79
Likewise, among WHI post-hysterectomy participants who
received estrogen alone, there was improvement in joint pain
compared with controls.80
The age, obesity, and military history features of our sample
may also contribute to the rates of muscle and joint pain
symptoms. Several reviews have documented the independent
effect of elevated BMI and age on the risk for osteoarthritis of
the knee,81–84 hip,82,83 and hand83 among both women and
men. Prospective cohort investigations and retrospective case
control studies have repeatedly demonstrated that BMI is an
independent risk factor for osteoarthritis with incremental
impact; as BMI progresses from normal-weight to obese, os-
teoarthritis risk increases.83 Similarly, in the Framingham
study,75 participants at baselinewithout knee osteoarthritis had
increased risk for this condition if they had higher baseline
BMI. Increasing age has also been associated with a 10-fold
increase in degenerative changes in the hand, knee, and hip.82
Military service is a characteristic of our sample that
may have influenced musculoskeletal symptom severity.
Musculoskeletal injuries are a major concern among military
personnel85 and the leading cause of disability.86 Military
women have twice the injury rates of men; almost half sustain
a musculoskeletal injury in initial training.87 Without longi-
tudinal data, it is difficult to determine if the prevalence and
severity of muscle and joint symptoms are a function of
menopause, comorbid obesity, or military service.
Strengths of the study included access to an ethnically
diverse national sample and electronic health record data to
accurately evaluate clinical features of diabetes. The cross-
sectional design precluded assessment of the temporal rela-
tionship of symptoms with menopause or diabetes, and
generalizability is limited to women veterans using VHA
services. The retrospective self-report of symptoms and age
of menopause are prone to bias. Without data regarding the
military service experience, or a detailed gynecological his-
tory, we cannot account for the impact of these respondent
characteristics on the menopause symptom experience.
Conclusions
In summary, a number of high-risk health conditions (obe-
sity, hypertension, depression, induced menopause) were re-
ported by postmenopausal women using the VHA for health
care. Although women with type 2 diabetes experience similar
symptoms, including joint pain, as their nonaffected peers,
glucose control was a key independent correlate of menopause
symptom severity along with the covariates of altered mood
and tobacco use. These findings substantiate the importance of
addressing postmenopausal symptoms in the clinical man-
agement of female veterans with diabetes receiving VHA
services. The data also suggest that interventions targeting
glucose control may improve the postmenopausal experience
of women with diabetes.
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